Findings

What do systematic reviews say?

628 questions · 651 findings · 39 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 167 · 25.7%GRADE not reported 47 · 7.2%Very low 80 · 12.3%Low 139 · 21.4%Moderate 174 · 26.7%High 44 · 6.8%

Oral propranolol vs placebo

Aesthetics · infantile haemangiomas (strawberry birthmarks) of the skin

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile haemangiomas of the skin 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical timolol vs placebo

Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile haemangiomas of the skin 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical timolol vs placebo

A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for infantile haemangiomas of the skin 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs placebo

Change (improvement) in disease severity (4 to 8 weeks) SMD (modified EASI score and SASSAD) · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 131 participants
Low

Montelukast vs placebo

Effect of long‐term control (> 3 months) · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs placebo

Adverse effects (4 to 8 weeks) · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 131 participants
Low

Montelukast vs placebo

Corticosteroid requirements · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Montelukast vs placebo

Reduction of pruritus · eczema

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Montelukast vs placebo

Improvement in quality of life · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Montelukast vs placebo

Need for emollient use · eczema

The review found no eligible studies for this question.

1 finding from 1 review

Leukotriene receptor antagonists for eczema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

SAEs · NSTI

Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.73 [0.32, 1.65]
1 study · 100 participants
Low

IVIg vs placebo

Survival time · NSTI

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low

IVIg vs placebo

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

AB103 vs placebo

All‐cause mortality · NSTI

It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 0.34 [0.05, 2.16]
1 study · 43 participants
Very low

AB103 vs placebo

SAEs · NSTI

It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.49 [0.52, 4.27]
1 study · 43 participants
Very low

AB103 vs placebo

Survival time · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

AB103 vs placebo

Assessment of long‐term morbidity · NSTI

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

All‐cause mortality · NSTI

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
RR 1.17 [0.42, 3.23]
1 study · 100 participants
Low

R‐salbutamol 0.5% topical cream vs placebo

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

R‐salbutamol 0.5% topical cream vs placebo

At least 50% reduction in erythema · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported